Phase 1 Trial for Prolanta in Advanced Ovarian Cancer Recruiting for Second Dose Group

Phase 1 Trial for Prolanta in Advanced Ovarian Cancer Recruiting for Second Dose Group
Oncolix has started enrolling patients for the second dosing group in a Phase 1 trial of Prolanta for the treatment of advanced ovarian cancer. In the first dose group, Prolanta caused no serious adverse events or dose-limiting toxicity. Prolanta is a prolactin receptor antagonist (or blocker) that has been shown to be effective in cancer

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *